Medpace Holdings (MEDP) Stock Forecast & Price Target

Compare

631 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MEDP Analyst Ratings

Hold

2 Buy

6 Hold

2 Sell

Based on 10 analysts giving stock ratings to

Medpace

Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MEDP Stock 12 Month Forecast

Average Price Target

$421.22

▼(-8.29% Downside)

Based on 10 Wall Street analysts offering 12 month price targets for Medpace Holdings in the last 3 months. The average price target is $421.22 with a high forecast of $510.00 and a low forecast of $300.00. The average price target represents a -8.29% change from the last price of $459.29.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"296":"$296","511":"$511","349.75":"$349.8","403.5":"$403.5","457.25":"$457.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":510,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$510.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":421.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$421.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$300.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[296,349.75,403.5,457.25,511],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,321.06,335.59384615384613,350.1276923076923,364.66153846153844,379.1953846153846,393.72923076923075,408.26307692307694,422.79692307692306,437.33076923076925,451.8646153846154,466.39846153846156,480.9323076923077,495.4661538461538,{"y":510,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,321.06,328.7646153846154,336.46923076923076,344.17384615384617,351.8784615384615,359.58307692307693,367.28769230769234,374.9923076923077,382.6969230769231,390.4015384615385,398.10615384615386,405.81076923076927,413.5153846153846,{"y":421.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,321.06,319.44,317.82,316.2,314.58,312.96,311.34,309.72,308.1,306.48,304.86,303.24,301.62,{"y":300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":407.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":385.16,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355.27,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":333.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":319.56,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":342.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.23,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":349.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":321.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$510.00

Average Price Target$421.22

Lowest Price Target$300.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dan Leonard

UBS

$300→$305

Sell

-33.59%

Downside

Downgraded

07/29/25

Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS

Ann Hynes

Mizuho Securities

$328→$510

Buy

11.04%

Upside

Reiterated

07/25/25

Mizuho Securities Keeps Their Buy Rating on Medpace Holdings (MEDP)Mizuho analyst Ann Hynes raised the price target on Medpace (NASDAQ: MEDP) to $510.00 (from $328.00) while maintaining a Outperform rating.

Cira Diagnissa

TR | OpenAI - 4o

$539→$499

Buy

8.65%

Upside

Reiterated

07/24/25

Eric Coldwell

Robert W. Baird

$313→$490

Hold

6.69%

Upside

Reiterated

07/23/25

Medpace price target raised to $490 from $313 at BairdMedpace price target raised to $490 from $313 at Baird

Michael Cherny

Leerink Partners

$307→$455

Hold

-0.93%

Downside

Reiterated

07/23/25

Medpace Holdings: Hold Rating Amid Stock Surge and Uncertain Burn Rate Sustainability

Charles Rhyee

TD Cowen

$283→$366

Sell

-20.31%

Downside

Downgraded

07/23/25

TD Cowen Remains a Hold on Medpace Holdings (MEDP)

Max Smock

William Blair

―

Hold

―

Reiterated

07/23/25

Medpace Holdings: Balancing Strong Q2 Results with Market UncertaintiesWe view the following as key risks for Medpace: 1) a slowdown in the R&D spending environment due to lower end-market pricing or other exogenous factors; 2) a material reduction in the amount of biotech funding; and 3) increased competitive pricing pressure in the clinical CRO industry. Blair | Building | 150 North Riverside Plaza | Chicago, IL 60606 | +1 312 236 1600 | www.williamblair.com This is not in any sense a solicitation or offer of the purchase or sale of securities. The factual statements herein have been taken from sources we believe to be reliable, but such statements are made without any representation as to accuracy or completeness or otherwise. Opinions expressed are our own unless otherwise stated. Prices shown are approximate.

Justin Bowers

Deutsche Bank

$270→$430

Hold

-6.38%

Downside

Reiterated

07/23/25

Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank

Jailendra Singh

Truist Financial

$298→$436

Hold

-5.07%

Downside

Reiterated

07/23/25

Truist Financial Sticks to Its Hold Rating for Medpace Holdings (MEDP)

Luke Sergott

Barclays

$300

Hold

-34.68%

Downside

Reiterated

07/22/25

Barclays Keeps Their Hold Rating on Medpace Holdings (MEDP)

David Windley

Jefferies

$300→$285

Hold

-37.95%

Downside

Reiterated

04/21/25

Medpace (MEDP) PT Lowered to $285 at JefferiesJefferies analyst David Windley lowered the price target on Medpace (NASDAQ: MEDP) to $285.00 (from $300.00) while maintaining a Hold rating.

Unknown Analyst

Redburn Atlantic

Not Ranked

Redburn Atlantic

$404

Buy

-12.04%

Downside

Initiated

10/14/24

Redburn-Atlantic starts Medpace (MEDP) at BuyRedburn-Atlantic initiates coverage on Medpace (NASDAQ: MEDP) with a Buy rating and a price target of $404.00.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Dan Leonard

UBS

$300→$305

Sell

-33.59%

Downside

Downgraded

07/29/25

Medpace downgraded to Sell from Neutral at UBSMedpace downgraded to Sell from Neutral at UBS

Ann Hynes

Mizuho Securities

$328→$510

Buy

11.04%

Upside

Reiterated

07/25/25

Cira Diagnissa

TR | OpenAI - 4o

$539→$499

Buy

8.65%

Upside

Reiterated

07/24/25

Eric Coldwell

Robert W. Baird

$313→$490

Hold

6.69%

Upside

Reiterated

07/23/25

Medpace price target raised to $490 from $313 at BairdMedpace price target raised to $490 from $313 at Baird

Michael Cherny

Leerink Partners

$307→$455

Hold

-0.93%

Downside

Reiterated

07/23/25

Medpace Holdings: Hold Rating Amid Stock Surge and Uncertain Burn Rate Sustainability

Charles Rhyee

TD Cowen

$283→$366

Sell

-20.31%

Downside

Downgraded

07/23/25

TD Cowen Remains a Hold on Medpace Holdings (MEDP)

Max Smock

William Blair

―

Hold

―

Reiterated

07/23/25

Justin Bowers

Deutsche Bank

$270→$430

Hold

-6.38%

Downside

Reiterated

07/23/25

Medpace price target raised to $430 from $270 at Deutsche BankMedpace price target raised to $430 from $270 at Deutsche Bank

Jailendra Singh

Truist Financial

$298→$436

Hold

-5.07%

Downside

Reiterated

07/23/25

Truist Financial Sticks to Its Hold Rating for Medpace Holdings (MEDP)

Luke Sergott

Barclays

$300

Hold

-34.68%

Downside

Reiterated

07/22/25

Barclays Keeps Their Hold Rating on Medpace Holdings (MEDP)

David Windley

Jefferies

$300→$285

Hold

-37.95%

Downside

Reiterated

04/21/25

Medpace (MEDP) PT Lowered to $285 at JefferiesJefferies analyst David Windley lowered the price target on Medpace (NASDAQ: MEDP) to $285.00 (from $300.00) while maintaining a Hold rating.

Unknown Analyst

Redburn Atlantic

Not Ranked

Redburn Atlantic

$404

Buy

-12.04%

Downside

Initiated

10/14/24

Redburn-Atlantic starts Medpace (MEDP) at BuyRedburn-Atlantic initiates coverage on Medpace (NASDAQ: MEDP) with a Buy rating and a price target of $404.00.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medpace Holdings

1 Month

xxx

Success Rate

3/7 ratings generated profit

Average Return

+0.07%

downgraded a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.86% of your transactions generating a profit, with an average return of +0.07% per trade.

3 Months

xxx

Success Rate

2/6 ratings generated profit

Average Return

-3.47%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -3.47% per trade.

1 Year

Ann HynesMizuho Securities

Success Rate

5/6 ratings generated profit

Average Return

+16.90%

reiterated a buy rating 20 days ago

Copying Ann Hynes's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +16.90% per trade.

2 Years

xxx

Success Rate

6/6 ratings generated profit

Average Return

+23.53%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +23.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MEDP Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MEDP has received 10 Buy Ratings, 14 Hold Ratings, and 2 Sell Ratings. MEDP average Analyst price target in the past 3 months is 421.22.

Each month's total comprises the sum of three months' worth of ratings.

MEDP Financial Forecast

MEDP Earnings Forecast

Next quarter’s earnings estimate for MEDP is $3.52 with a range of $3.35 to $3.82. The previous quarter’s EPS was $3.10. MEDP beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.29% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.

MEDP Sales Forecast

Next quarter’s sales forecast for MEDP is $629.30M with a range of $542.00M to $671.01M. The previous quarter’s sales results were $603.31M. MEDP beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.63% of the time in the same period. In the last calendar year MEDP has Outperformed its overall industry.

MEDP Stock Forecast FAQ

What is MEDP’s average 12-month price target, according to analysts?

Based on analyst ratings, Medpace Holdings’s 12-month average price target is 421.22.

What is MEDP’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MEDP, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MEDP a Buy, Sell or Hold?

Medpace Holdings has a consensus rating of Hold which is based on 2 buy ratings, 6 hold ratings and 2 sell ratings.

What is Medpace Holdings’s price target?

The average price target for Medpace Holdings is 421.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $510.00 ,the lowest forecast is $300.00. The average price target represents -8.29% Decrease from the current price of $459.29.

What do analysts say about Medpace Holdings?

Medpace Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of MEDP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Medpace Holdings (MEDP) Stock Forecast & Price Target

MEDP Analyst Ratings

MEDP Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Medpace Holdings

MEDP Analyst Recommendation Trends

MEDP Financial Forecast

MEDP Earnings Forecast

MEDP Sales Forecast

MEDP Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts